Table I.
Baseline Characteristics of 1,486 patients with juxta-/pararenal aortic aneurysms undergoing fenestrated endovascular aneurysm repair
| Infraceliac Sealing zone (N=1246) | Supraceliac sealing zone (N=240) | p-value | |
|---|---|---|---|
|
| |||
| Age | 74 [IQR 68, 79] | 75 [IQR 69, 80] | .048 |
| Female Sex | 274 (22%) | 45 (19%) | .48 |
| Race | .79 | ||
| Non-White Hispanic | 1092 (88%) | 207 (86%) | |
| Black | 55 (4.4%) | 7 (2.9%) | |
| Asian | 18 (1.4%) | 4 (1.7%) | |
| Hispanic | 14 (1.1%) | 5 (2.1%) | |
| Other | 8 (0.6%) | 1 (0.4%) | |
| Hypertension | 1087 (87%) | 220 (92%) | .053 |
| Diabetes | 162 (13%) | 39 (16%) | .63 |
| Prior MI | 260 (21%) | 53 (22%) | >.99 |
| Prior CHF | .21 | ||
| NYHA I/II | 135 (11%) | 36 (15%) | |
| NYHA III/IV | 21 (1.7%) | 4 (1.7%) | |
| Smoking (ever) | 1123 (90%) | 217 (90%) | .87 |
| COPD | 322 (26%) | 68 (28%) | .52 |
| Obese (BMI≥30) | 383 (31%) | 71 (30%) | .92 |
| Renal status | .24 | ||
| eGFR>60 mL/min/1.73m2 | 756 (61%) | 136 (57%) | |
| eGFR30-60mL/min/1.73m2 | 442 (36%) | 92 (38%) | |
| eGFR<30mL/min/1.73m2 | 31 (2.5%) | 11 (4.6%) | |
| Dialysis | 3 (0.3%) | 0 (0%) | |
| Prior PAD | 96 (7.7%) | 12 (9.6%) | .40 |
| Anemia (Hgb<10mg/dL) | 60 (4.8%) | 17 (7.1%) | .32 |
| Aspirin | 831 (67%) | 176 (73%) | .079 |
| P2Y12-inhibitor | 238 (19%) | 39 (16%) | .34 |
| Statin | 924 (74%) | 192 (80%) | .047 |
| Beta Blocker | 746 (60%) | 150 (63%) | 0.3 |
| ACE/ARB | 639 (51%) | 151 (63%) | .004 |
| Prior Aortic Surgery | 61 (4.9%) | 36 (15%) | <.001 |
| Prior Infrarenal Endovascular Aneurysm Repair | 2.3% | 11% | |
MI= myocardial infarction; CHF = congestive heart failure; COPD= chronic obstructive pulmonary disease; BMI = body mass index; eGFR = estimated Glomerular Filtration; PAD = peripheral arterial disease; Hgb = Hemoglobin; ACE = angiotensin converting enzyme; ARB = angiotensin II receptor blocker